PT2448968T - ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL - Google Patents

ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL

Info

Publication number
PT2448968T
PT2448968T PT107397010T PT10739701T PT2448968T PT 2448968 T PT2448968 T PT 2448968T PT 107397010 T PT107397010 T PT 107397010T PT 10739701 T PT10739701 T PT 10739701T PT 2448968 T PT2448968 T PT 2448968T
Authority
PT
Portugal
Prior art keywords
alzheimer
oligomers
therapeutic
disease
diagnostic methods
Prior art date
Application number
PT107397010T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of PT2448968T publication Critical patent/PT2448968T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT107397010T 2009-06-29 2010-06-29 ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL PT2448968T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
PT2448968T true PT2448968T (pt) 2021-04-30

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107397010T PT2448968T (pt) 2009-06-29 2010-06-29 ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP2448968B1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
EP2539366B1 (en) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
CN103459421B (zh) * 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
HRP20210680T1 (hr) 2014-07-10 2021-06-11 Bioarctic Ab POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL
CN107849125A (zh) 2015-07-21 2018-03-27 生命北极神经科学公司 用于治疗靶向聚集的肽的创伤性脑损伤的方法
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CA3107370A1 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
JPWO2021006212A1 (enExample) * 2019-07-08 2021-01-14
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
HUE072262T2 (hu) 2020-06-26 2025-11-28 Bioarctic Ab Alfa-szinuklein protofibrillum-kötõ antitestek
AU2022307687A1 (en) 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
EP4395821A1 (en) 2021-08-30 2024-07-10 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
JP2025506389A (ja) 2022-02-02 2025-03-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 p-タウ181レベルを使用した治療方法
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
TW202607032A (zh) 2024-06-20 2026-02-16 瑞典商生物極公司 雙特異性結合分子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
EP1571158B1 (en) * 1999-08-04 2009-10-14 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) * 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
BRPI0709050B1 (pt) * 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
EP2207568B1 (en) * 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
DK2282758T3 (en) * 2008-04-29 2019-02-25 Bioarctic Ab ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS

Also Published As

Publication number Publication date
AU2010267640A1 (en) 2012-01-19
CY1124034T1 (el) 2022-05-27
CA2765602C (en) 2021-05-25
SMT202100237T1 (it) 2021-05-07
SI2448968T1 (sl) 2021-07-30
HUE053949T2 (hu) 2021-08-30
JP2012532094A (ja) 2012-12-13
JP2019218362A (ja) 2019-12-26
EP2448968A1 (en) 2012-05-09
JP6884025B2 (ja) 2021-06-09
LT2448968T (lt) 2021-05-10
PL2448968T3 (pl) 2021-09-13
HRP20210611T1 (hr) 2021-05-28
CA2765602A1 (en) 2011-01-06
EP3892633A1 (en) 2021-10-13
WO2011001366A1 (en) 2011-01-06
AU2010267640B2 (en) 2015-03-05
US20230295283A1 (en) 2023-09-21
ES2864049T3 (es) 2021-10-13
US20120100129A1 (en) 2012-04-26
DK2448968T3 (da) 2021-04-12
EP2448968B1 (en) 2021-01-27
JP2017197531A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
HUE041223T2 (hu) Antitestek és vakcinák alfa-szinukleinnel összefüggõ betegségek terápiás és diagnosztikai eljárásaiban történõ alkalmazásra
ZA201107862B (en) Intrauterine system for use in medical treatment
PL2393399T3 (pl) Materac przeznaczony do użytku w domach opieki i szpitalach
LT2539366T (lt) Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose
LT2758433T (lt) Alzheimerio ligos tau-sąlygojamos patologijos terapija ir diagnostika baltymų pagrindu
ZA201107085B (en) Indolizine derivative and use thereof for medical purposes
IL220684A (en) Anaphylactic therapy for Alzheimer's and the aging brain
IL216702A0 (en) Pharmaceutical composition for use in medical and veterinary ophthal mology
EP2182978A4 (en) TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
PT2405928T (pt) Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
PL2410922T3 (pl) Urządzenie do przeprowadzania procedur diagnostycznych i/lub terapeutycznych
GB201121597D0 (en) Polyurethane oligomers for use in restorative dentistry
GB0918392D0 (en) Diagnostic and therapeutic methods
ZA201106056B (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
GB0908868D0 (en) Depsipeptide and their therapeutic use
PT2470066E (pt) Método não invasivo para avaliação da perfusão de tecidos num doente
EP2565184A4 (en) THERAPEUTIC AGENT AND CONSERVATIVE AGENT AGAINST ALZHEIMER'S DISEASE
GB0912665D0 (en) Force-transmitting element for use in medical catheters
GB0905970D0 (en) Depsipeptides and their therapeutic use
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
PL2459721T3 (pl) Udoskonalony system ekspresji ludzkiej długiej pentraksyny i jego zastosowania
IL219256A0 (en) System and method for noninvasive tissue examination
GB0910048D0 (en) Methods and preparations for curing multiple organ dysfunction in clinically ill patients
GB0909894D0 (en) Methods and preparations for curing multiple organ dysfunction in clinically ill patients
GB201008106D0 (en) Cell protective peptides for treating diseases and disorders associated with tissue damage